Wassil Jim, the Chief Scientific Officer and COO of Vaxcyte, Inc., has reported several stock transactions in a recent SEC filing. The transactions, which occurred on November 2, 2026, include both the acquisition and sale of common stock. This activity is significant as it reflects Jim's ongoing confidence in the company's prospects and may influence investor sentiment.

Vaxcyte, Inc., a company based in San Carlos, California, operates in the biological products sector, specifically focusing on the development of vaccines and other biological products. The company was previously known as SutroVax, Inc. and has undergone a name change in July 2015. Vaxcyte is publicly traded under the ticker symbol PCVX.

According to the filing, Jim acquired 2,250 shares of Vaxcyte common stock at a price of $5.35 per share. Additionally, he sold 1,907 shares at a weighted average price of $60.779, and another 343 shares at a weighted average price of $61.57. Following these transactions, Jim holds a total of 145,435 shares of the company.

This activity may have implications for other stakeholders, including investors and analysts monitoring Vaxcyte's performance. The filing indicates that the sales were executed under a Rule 10b5-1 trading plan, which allows company insiders to sell shares in a predetermined manner, reducing the risk of insider trading allegations.

The filing does not specify what actions might follow these transactions, leaving some uncertainty regarding future stock movements or additional disclosures.